Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Kantelis

Clinical Nurse Specialist, Psychiatric/Mental Health Mission Viejo, CA Physician Assistant

NPI 1881047892 CMS profile 11067851

26024 Acero, Mission Viejo, CA 92691

Open in the dashboard

General payments

$24,877

897 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Kantelis of Mission Viejo, CA is reported in the CMS Open Payments database as having received $24,877 across 897 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,807 212
2024 General $2,971 109
2023 General $6,118 253
2022 General $5,116 232
2021 General $1,864 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Kantelis
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Sarah Kantelis were reported at $8,807. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Sarah Kantelis Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,864 $153 $44–$540 $132
2022 $5,116 $207 $60–$748 $149
2023 $6,118 $197 $55–$898 $160
2024 $2,971 $189 $49–$804 $164
2025 $8,807 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $6,884 140 payments
  2. Janssen Pharmaceuticals, Inc $2,429 73 payments
  3. Vanda Pharmaceuticals Inc. $2,064 69 payments
  4. Otsuka America Pharmaceutical, Inc. $1,908 98 payments
  5. Supernus Pharmaceuticals, Inc. $1,604 57 payments
  6. ITI, Inc. $1,445 75 payments
  7. Neurocrine Biosciences, Inc. $1,144 48 payments
  8. Teva Pharmaceuticals USA, Inc. $1,054 41 payments
  9. Alkermes, Inc. $992 50 payments
  10. Lundbeck LLC $653 35 payments
  11. Other $4,700 211 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $21,064 889 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 3 payments
  3. Education $63 5 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $4,274 30 payments
  2. VRAYLAR Neuroscience $2,533 106 payments
  3. FANAPT $2,064 69 payments
  4. SPRAVATO $2,052 63 payments
  5. HETLIOZ $1,950 65 payments
  6. REXULTI $1,532 82 payments
  7. CAPLYTA $1,195 62 payments
  8. QELBREE $1,061 44 payments
  9. INGREZZA $1,008 41 payments
  10. LYBALVI $861 44 payments
  11. Other $13,010 590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

589

Median for Physician Assistant: 241

Drug cost

$42,571

Median for Physician Assistant: $4,110

Branded share of claims

14.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 19 $27,759
Trintellix Vortioxetine Hydrobromide Brand 16 $8,848
Duloxetine Hcl Generic 80 $1,121
Trazodone Hcl Generic 39 $609
Quetiapine Fumarate Generic 32 $545
Bupropion Xl Bupropion Hcl Brand 38 $533
Hydroxyzine Pamoate Generic 36 $484
Mirtazapine Generic 27 $363
Olanzapine Generic 21 $314
Prazosin Hcl Generic 27 $292

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$5,686

Medicare's payments for the services billed

Medicare patients

26

Average age 62

Services billed

95

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 65%
Arthritis 46%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$594 19 —
Qelbree
$378 — —
SPRAVATO
$295 — —
Auvelity
$267 — —
CAPLYTA
$259 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

897 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record